According to the authoritative forecast of the International Diabetes Federation, the number of diabetes patients in China may increase to 174 million in 2045!

This number really shocked the Chinese people. Are there really so many? You know, the number of diabetes patients in China in 2023 will reach 141 million, with an incidence rate of 12.8%. The number of diabetes patients in China ranks first in the world! In recent years, diabetes has become younger in China. According to a report in 2020, the prevalence of diabetes among residents aged 18 and above in China has reached 11.9%. This set of data once again sounded the alarm for the health of the Chinese people!

You should know that diabetes is a chronic disease, and its typical symptoms are "three more and one less". "Three more" means drinking more, eating more, and urinating more; "one less" mainly refers to weight loss and lack of physical strength. Therefore, the diet, work and rest, and exercise of diabetic patients are particularly important. Irregular diet, staying up late, lack of exercise, smoking and drinking are all risk factors for diabetes.

Diabetes is easy to make people turn pale, but most people's impression of diabetes is still stuck in the misunderstanding that "eating too much sugar will cause the disease". They think that if they eat less sugar, they will not get diabetes. Some people are even afraid of getting diabetes and dare not eat watermelon in summer. Is this really the case? This view is definitely one-sided. As a chronic endocrine metabolic disease, the causes of diabetes are complex, including genetic factors, improper lifestyle and stress. The root cause is insufficient secretion or dysfunction of insulin in the human body, which leads to high blood sugar. Eating too much sugar may cause high blood sugar, but it is not the only factor that induces diabetes. Frequent intake of too much sugar (here refers to sugar in a narrow sense, foods or candies with high sugar content) will cause obesity, increase the burden on the pancreas, and cause abnormal insulin secretion, thus causing diabetes. Diabetes is divided into type 1 diabetes, type 2 diabetes, and special types of diabetes. Type 2 accounts for more than 90% of all diabetic patients. For the comprehensive management of type 2 diabetes, it is necessary to combine regular diet, appropriate exercise, blood sugar monitoring, rational medication, and a healthy lifestyle, which is the key to controlling blood sugar stability.

In fact, the terrible thing about diabetes is its complications. It may increase the risk of cardiovascular and cerebrovascular diseases, cause retinopathy, and cause diabetic foot. It has a high disability and mortality rate, which brings a heavy burden to families and society. It has become one of the major global public health issues. In China, diabetes prevention and treatment has been written into the "Healthy China 2030" planning outline. The National Health and Health Department requires strengthening the diabetes prevention and treatment system, improving the level of diagnosis and treatment, improving the level of diabetes drug supply guarantee, and improving the quality of life of patients. In recent years, the country has accelerated the research and development of diabetes treatment drugs. The launch of each innovative hypoglycemic drug will undoubtedly bring new hope and gospel to diabetic patients.

On June 28, 2024, the innovative drug "Fogliptin Benzoate Tablets" (trade name: Xinliting) for the treatment of type 2 diabetes obtained a drug registration certificate issued by the State Food and Drug Administration and was approved for marketing, providing a new option for the treatment of adult patients with type 2 diabetes.
Xinliting (Folagliptin Benzoate Tablets) is a dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibitors are one of the commonly used treatments for type 2 diabetes and have many advantages, such as: oral administration, can be taken before or after meals; no increased risk of hypoglycemia, few gastrointestinal side effects; no increased incidence of cardiovascular events, good safety and tolerability, etc. Xinliting (Folagliptin Benzoate Tablets) is used to improve blood sugar control in adult patients with type 2 diabetes (including monotherapy, and combined therapy when metformin hydrochloride alone cannot effectively control blood sugar).

It is reported that Xinliting (Folagliptin Benzoate Tablets) is promoting hospital access and medical insurance access, and will be put into clinical use as soon as possible to meet the medication needs of diabetic patients.

https://news.yaozh.com/archive/44377.html